Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04976283
Other study ID # AKUH-GTZ-DM-005-21
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date September 15, 2021
Est. completion date November 15, 2023

Study information

Verified date March 2022
Source Getz Pharma
Contact Azra Rizwan, FCPS
Phone +923212655271
Email azra.rizwan@aku.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin and/or DDP4 inhibitors.


Description:

To compare the effect of pioglitazone with or without Metformin and/or DPP4 inhibitor (no SGLT2 inhibitor) on improvement of NAFLD parameters, versus The effect of SGLT inhibitor with or without metformin and/or DPP4 inhibitor (no pioglitazone) on NAFLD parameters and versus Pioglitazone with or without metformin and/or DPP4 inhibitor, plus empagliflozin on improvement of NAFLD parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 123
Est. completion date November 15, 2023
Est. primary completion date May 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patient who give informed consent voluntarily - Type 2 diabetic patient having age from 18 years to 60 years - HbA1C = 7.0 % - Diabetes diagnosis of = 5 years (longer duration more likely to be associated with use of multiple drug regimens for glycemic control which may affect liver fat mass) - Either treatment naïve or on metformin alone or metformin/DPP4i combination - Absolute weight < 100kg; BMI < 45 (fibro scan machine cannot accommodate heavier individuals) - Documented hepatosteatosis (If the fibroscan reveals S1 (mild fatty liver: 11-33% fatty liver) to S3 (severe fatty liver: > 67% fatty liver) liver fat Exclusion Criteria: - Hba1c = 9% and/or blood sugar > 250mg/dl - History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requiring frequent dose adjustment, or Cushings syndrome) - History of anti-obesity medication use within 3 months of consent for study enrollment or weight loss procedure(bariatric surgery) within same duration - History of use of SGLT 2 inhibitors, glitazones, Glucagon-like peptide (GLP) 1 agonists 3 months prior to study enrollment as they influence liver fat - History of use of insulin/sulphonylurea 3 months prior to study enrollment owing to weight gain and potential increase in liver fat conferred by these agents - History of vitamin E use (400mg twice daily) within 3 months of study enrollment - Drug induced liver disease or active substance abuse (cannabonnoid-derived substances like heroin, cocaine, amphetamines) based on history and/or laboratory tests - Drugs known to be associated with hepatic steatosis like steroids, traditional homeopathic medication (likely to contain steroids), methotrexate, valproate, tamoxifen, amiodarone. - Alcohol use (History of alcoholism or a greater than recommended alcohol intake (> 21 standard drinks on average per week in men and > 14 standard drinks on average per week in women) - Severe hepatic impairment (ALT levels > 3 times upper limit normal) - Hepatitis B/C hepatitis (based on positive Hepatitis B surface antigen, Anti Hepatitis C antibodies positive - Autoimmune hepatitis (in case of females), based on positive Anti-nuclear Antibody (ANA) (homogenous, high titre) - Positive Human Immunodeficiency Virus ( HIV) test as this could influence liver functions - Pregnant or lactating women/ plans for pregnancy over proceeding 13 months - Obstructive liver disease on the basis of laboratory and imaging studies - Chronic renal failure, or Glomerular Filtration Rate (GFR) < 30 mls/minute (as estimated by the MDRD equation) - Chronic heart failure, history of acute coronary artery disease or cerebrovascular accident within 3 months of consent for study enrollment, based on history and/or cardiac imaging - History of recurrent Urinary Tract Infections (UTI's) or mycotic infections - Presence of ketones on Urine Analysis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pioglitazone
Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
Empagliflozin
Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
Pioglitazone + Empagliflozin
Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).

Locations

Country Name City State
Pakistan Aga Khan University Hospital Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Getz Pharma

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Urine Albumin to Creatinine Ratio (UACR) Number of participants reported change in Urine Albumin to Creatinine Ratio (UACR) from baseline to end of treatment 12 months
Other Change in Systolic and Diastolic blood pressure Number of participants reported change in Systolic and Diastolic blood pressure from baseline to end of treatment 12 months
Primary Change in radiologic liver parameters Number of participants reported change in liver fat content from baseline, as quantified by fibroscan 12 months
Secondary Change in liver enzymes Number of participants reported change in liver enzymes levels including ALT, AST and GGT 12 months
Secondary Change in Fibrosis-4 (FIB-4) Score and NAFLD Fibrosis Score Number of participants reported change in FIB-4 Score and NAFLD Fibrosis Score. Fibrosis-4 scores range from 0 to 4, where <1.45 indicates absence of cirrhosis; score between 1.45 - 3.25 are deemed inconclusive and score >3.25 indicates cirrhosis. 12 months
Secondary Change in body weight Number of participants reported change in body weight from baseline (treat to target response of at least 5% of baseline at 6 months, 10% baseline over 12 months). 12 months
Secondary Change in waist circumference (WC) Number of participants reported change in waist circumference (WC) 12 months
Secondary Change in liver fat mass with total body fat (TBF) Comparison of baseline and end of treatment liver fat mass with total body fat (TBF) using a Body Composition Monitor 12 months
Secondary Change in HbA1C levels (< 7.0%) Number of participants reported change in HbA1C levels from baseline to end of treatment 12 months
Secondary Change in Fasting Blood Sugar (FBS) Number of participants reported change in Fasting Blood Sugar (FBS) from baseline to end of treatment 12 months
Secondary Change in Lipid profile Number of participants reported change in Fasting triglycerides (TG), Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) from baseline to end of treatment 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2